eScholarship
metadata only
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalize
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area#676015
- From sequences to strategies: Early detection of new SARS-CoV-2 variants via genetic distance to reduce hospitalizations#631449
- Tracking the evolution of biomarker efficacy in SARS-CoV-2: a global meta-analyses series#325041
- Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxis#451904
- Rapid Determination of SARS-CoV-2 antibodies using a bedside, point-of-Care, serological test#391821
Record · ID 1373321
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive